Clinical trials

108

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

SAMe in Prevention of Oxaliplatin-associated Liver Injury

This is an open-label, phase II study that may provide evidence that taking S-adenosylmethionine (SAMe) supplementation prevents oxaliplatin, a type of chemotherapy drug, associated liver toxicity in patients with resectable colorectal liver metastases. Resectable means that it is able to removed with surgery. Patients will take two SAMe tablets in the morning and one tablet in the evening for 3-6 months (about 6-8 cycles of chemotherapy) in addition to oxaliplatin based chemotherapy followed by surgical removal of the colorectal liver metastases.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Cedars-Sinai Medical CenterUpdated: Nov 6, 2026Locations: 2
Eligibility criteria

Stage IV patients with resectable liver predominant metastatic colorectal cancer... [+12]

Currently participating in or has participated in a study of an investigational... [+22]

Status: Recruiting

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.

Participants needed: 52
Trial details
Phase: Phase 2Age: Up to 3Biological sex: AllType: InterventionalSponsor: St. Jude Children's Research HospitalUpdated: Nov 3, 2026Locations: 6
Eligibility criteria

Age from birth to age <3 years at the time of diagnosis (date of surgical resect... [+5]

Previous exposure to cytotoxic chemotherapy or radiotherapy [+46]

Status: Recruiting

Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma

This observational study follows patients with T4 stage sinonasal adenoid cystic carcinoma (a rare cancer of the nasal cavity/sinuses) who receive standard treatment: surgery followed by postoperative radiotherapy. The main goal is to measure the 3-year progression-free survival rate (the percentage of patients alive without cancer growth or spread). We will also assess overall survival, recurrence, side effects, and quality of life. This multicenter, prospective study will provide much-needed real-world data to improve patient counseling and guide future research.

Participants needed: 70
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Eye & ENT Hospital of Fudan UniversityUpdated: Nov 3, 2026Locations: 6
Eligibility criteria

Age 18 80 years, any gender; ECOG performance status 0 2; life expectancy ≥6 mon... [+7]

Progressive lung metastases within 6 months (new lesions or >20% increase); extr... [+6]

Status: Not yet recruiting

Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma

The purpose of this study is to test whether giving treatment before surgery helps babies who are newly diagnosed with Infant-Type Hemispheric Glioma (IHG) have safer and better surgery results.

Participants needed: 50
Trial details
Phase: Phase 2Age: Up to 60Biological sex: AllType: InterventionalSponsor: St. Jude Children's Research HospitalUpdated: Nov 4, 2026Locations: 1
Eligibility criteria

Patient with presumptive or suspected (new) diagnosis of Infant-Type Hemispheric... [+20]

Age > 60 months [+2]

Status: Recruiting

Activation Sarcoma: PROMIS and Mobility Evaluation in Sarcoma Patients

Sarcoma is a rare form of bone and soft tissue cancer, making up about 1% of all adult cancers. Management typically involves radiation therapy, chemotherapy, and surgical resection. Surgery is central to the treatment of bone and soft tissue sarcoma, yet post-surgical recovery is difficult to measure because of disease rarity, multiple different tumor types, and treatment variation. Therefore, the overall goal of the study is to use patient reported outcome measures and mobility data to define recovery trajectories in sarcoma patients undergoing surgery, and to evaluate a novel smartphone application (app) entailed Activation Health for collecting these data. Participants will download the Activation Health app on their smartphone. A demographics survey and multiple patient reported outcome measures will be administered remotely through the Activation Health app. Surveys will be completed preoperatively and at 6 weeks, 12 weeks, 6 months 12 months, 16 months, 20 months, and 24 months postoperatively. Additionally, the app will passively track mobility metrics such as daily step count, stairs climbed, and gait parameters throughout the study period. At the end of study participation, an additional surveys will be administered assess participant phone use habits and app function.

Participants needed: 800
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: University of CalgaryUpdated: Nov 2, 2026Locations: 4
Eligibility criteria

Age ≥ 18 years [+6]

Metastatic bone tumor [+5]

Status: Recruiting

Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer

Treatment of intrahepatic cholangiocarcinoma (ICC) remains difficult. Many patients have unresectable tumors, and survival after resection was only slightly improved with the use of adjuvant capecitabine. One of the major prognostic factors is the resection margin, patients with invaded (R1) or narrow (\<5mm) margins having a higher risk of recurrence. Selective Internal Radiation Therapy (SIRT) with Yttrium-90 microspheres (also known as SIRT) is an interesting treatment in unresectable ICC. In a phase 2 study, the investigators showed a response rate of 39% and a disease control rate of 98%. Interestingly, 9 of the 41 patients were able to see their tumors downstages to surgery. It was also recently suggested in a retrospective study that patients resected after SIRT had a better prognosis than patients that could be operated upfront, despite less favorable initial tumor characteristics. Given the absence of validated neoadjuvant treatment, the promising activity of SIRT and chemotherapy combination in the unresectable setting, and the prognostic significance of close surgical margins, the aim of this trial is therefore to study this combination treatment in the neoadjuvant setting of resectable ICC.

Participants needed: 62
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Center Eugene MarquisUpdated: Oct 23, 2026Locations: 7
Eligibility criteria

Age > 18 years-old, [+30]

Pulmonary shunt with dose >30Gy, [+2]

Status: Recruiting

Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)

This study is a multicenter, prospective, open-label clinical trial. It enrolls previously untreated patients with resectable stage IB-IIIB KRAS G12C mutation-positive NSCLC to evaluate the efficacy and safety of glesorasib sequentially combined with ivonescimab and chemotherapy as perioperative treatment for this patient population.

Participants needed: 32
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Guangdong Provincial People's HospitalUpdated: Oct 23, 2026Locations: 1
Eligibility criteria

Age Range: Males or females aged 18 years or older. [+16]

Previous receipt of any anti-tumor therapy for lung cancer (including adjuvant c... [+52]

Status: Recruiting

Immunotherapy and Nodal-Sparing Irradiation for T-Cell Induction and Unmasking of Tumor Antigenicity in the Microenvironment for Head and Neck Cancer

This is a non-comparative randomized Phase 2 study using the INITIUM regimen with or without elective nodal irradiation (ENI) delivered before surgery for resectable head and neck squamous cell carcinoma (HNSCC).

Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Medical College of WisconsinUpdated: Oct 19, 2026Locations: 1
Eligibility criteria

Patients 18 years or older. [+12]

HPV-positive squamous cell carcinoma of the oropharynx. [+18]

Status: Recruiting

Observational Approach Versus Surgical Intervention for Stones

The aims of the Observational Approach versus Surgical Intervention for Asymptomatic Stone (OASIS) trial are: 1) to determine whether observation compared to upfront surgery results in less healthcare-related life disruption due to kidney stones among children and adults with asymptomatic kidney stones; 2) to identify the groups benefiting the most from each strategy; and 3) to determine the preferences and values informing the choice between observation and upfront surgery.

Participants needed: 1,658
Trial details
Age: 6+Biological sex: AllType: InterventionalSponsor: Children's Hospital of PhiladelphiaUpdated: Oct 15, 2026Locations: 4
Eligibility criteria

Individuals age 6 or older [+8]

Untreated hydronephrosis or caliectasis [+7]

Status: Recruiting

dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy

This study is evaluating two treatment approaches for patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) who have a good response to 2-3 cycles of induction chemoimmunotherapy. Patients who achieve either a clinical complete response (cCR) or partial response (PR) will be eligible to join the study. After enrollment, patients will choose, together with their doctors, between surgery and definitive chemoradiotherapy (dCRT). Patients in the surgery group will undergo esophagectomy with lymph-node dissection. Patients in the dCRT group will receive radiotherapy together with chemotherapy. After surgery or dCRT, all patients will receive camrelizumab immunotherapy for up to 12 months if they have recovered sufficiently and have no evidence of disease progression. The study will compare the effectiveness and safety of these two treatment approaches and will assess whether dCRT can provide an organ-preserving treatment option for selected patients. The study will enroll approximately 120 patients.

Participants needed: 120
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Tianjin Medical University Cancer Institute and HospitalUpdated: Oct 15, 2026Locations: 1
Eligibility criteria

Volunteered to participate, cooperated with follow-up visits. [+14]

Prior surgery for esophageal cancer; [+20]

Status: Recruiting

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study

This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in resectable stage II-III non-small cell lung cancer.Finally, it provides new evidence-based medical evidence for the perioperative treatment of non-small cell lung cancer.

Participants needed: 34
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Qilu Hospital of Shandong UniversityUpdated: Oct 13, 2026Locations: 1
Eligibility criteria

Age 18-75 years old, gender is not limited; [+9]

A history of received treatment for current lung cancer, including radiotherapy... [+16]

Status: Recruiting

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC

Surgical intervention remains the primary treatment option for early-stage lung cancer. With the proven efficacy of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC), neoadjuvant immunotherapy has increasingly become a focal point of research. Blocking vascular endothelial growth factor (VEGF) not only inhibits the proliferation of vascular endothelial cells and the formation of new blood vessels but also improves the tumor microenvironment and enhances the infiltration of cytotoxic T lymphocytes within it. Simultaneously targeting the VEGF and PD-L1 pathways can create a synergistic anti-cancer effect. PM8002 injection is a bispecific antibody drug that targets both PD-L1 and VEGF, functioning as a dual-action agent that combines immune suppression and anti-angiogenesis. In patients with locally advanced stage II-III NSCLC, neoadjuvant therapy that concurrently targets PD-L1/VEGF in combination with chemotherapy can improve pathological response rates, provided that the safety of the drug combination is maintained. This approach offers additional benefits to patients, prolongs event-free survival (EFS), and improves prognosis.

Participants needed: 290
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Pulmonary Hospital, Shanghai, ChinaUpdated: Oct 7, 2026Locations: 5
Eligibility criteria

The patient shall sign the Informed Consent Form. [+10]

Patients with lung adenocarcinoma with confirmed EGFR mutations or ALK rearrange... [+12]

Status: Recruiting

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.

Participants needed: 250
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: European Organisation for Research and Treatment of Cancer - EORTCUpdated: Oct 7, 2026Locations: 176
Eligibility criteria

STRASS 2 [+33]

Sarcoma originating from bone structure, abdominal or gynecological viscera [+23]

Status: Recruiting

Identification of New Biomarkers in Haemophilic Arthropathy Through Transcriptome Analysis

Chronic arthropathy is one of the most common complications of haemophilia, affecting up to 90 per cent of patients aged 4 and over in at least one joint. the study aims to assess gene expression in biological samples collected via synovectomy and joint replacement surgery, as well as in peripheral blood, in patients with severe haemophilia A or B; to compare these data with those from patients with osteoarthritis and rheumatoid arthritis; and to correlate the gene expression data with information relating to the clinical and laboratory phenotype, the history of inhibitors, and ultrasound and histological findings.

Participants needed: 20
Trial details
Biological sex: AllType: InterventionalSponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoUpdated: Oct 9, 2026Locations: 1
Eligibility criteria

Diagnosis of severe haemophilia A or B [+2]

Current presence of an inhibitor (anti-FVIII or anti-FIX); [+1]

Status: Recruiting

Metastasis-directed Therapy for Oligometastases of Breast Cancer

OLIGAMI trial is a multi-institutional, two-arm, open-label, randomized controlled phase III trial being conducted with the participation of 50 hospitals belonging to Japan Clinical Oncology Group. After the first registration, all patients will be performed in a 12-week, subtype-specific, systemic therapy consisting of CDK4/6 inhibitors with hormonal therapy for luminal BC, docetaxel with trastuzumab and pertuzumab for HER2-positive BC, chemotherapy with immune checkpoint inhibitors for triple-negativeBC expressing PD-L1, and olaparib for cases harboring BRCA mutations. For other triple-negative BC, chemotherapy will be administered. If this 12-week systemic therapy does not cause any progression or complete response, patients proceed to second registration for randomization; arm A continues same systemic therapy alone, and arm B performs MDT followed by same systemic therapy. The MDT will involve either RT or surgery, and RT will involve mainly SBRT and partly conventional RT.

Participants needed: 146
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Tokyo Medical and Dental UniversityUpdated: Oct 7, 2026Locations: 1
Eligibility criteria

Histologically diagnosed as invasive breast cancer. Biopsy from oligometastasis... [+24]

Active malignancies curatively treated with no evidence of disease for >= 5 year... [+12]

Status: Recruiting

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality. Cases of EC in China account for over 50% of the global total, with squamous cell carcinoma being the primary pathological type. Locally advanced EC (LAEC), particularly cases where radical surgical resection is not feasible, exhibits high recurrence rates and low 5-year survival rates. However, studies have shown that patients with LAEC who undergo comprehensive treatment followed by surgery experience significantly prolonged survival and improved quality of life compared to those who do not receive surgical intervention. Current conversion treatment regimens under investigation include: chemotherapy alone, chemoradiotherapy, immunotherapy combined with chemotherapy, and immunotherapy combined with chemoradiotherapy-each of these approaches has distinct advantages and limitations. Immunochemotherapy has emerged as a current research focus: it not only demonstrates significantly superior efficacy compared to chemotherapy alone but also exhibits lower cumulative toxicity than radiotherapy-combined conversion regimens, resulting in a more favorable overall benefit-risk ratio. As such, it represents the most promising conversion treatment strategy. Retrospective and prospective clinical studies have shown that low-dose radiotherapy targeting the small intestine can enhance the anti-tumor response of immune checkpoint inhibitors (ICIs) in patients with advanced solid tumor, prolong their overall survival, and increase the incidence of the abscopal effect. Further mechanistic investigations have revealed that intestinal low-dose radiotherapy (ILDR) may augment the immune cancerous lethality by modulating the gut microbiota and their metabolic profiles. Based on the findings from these preliminary studies, the current research plans to conduct a prospective phase II single-arm clinical trial to investigate the efficacy and safety of ILDR combined with immunochemotherapy as conversion therapy in patients with borderline resectable or unresectable esophageal squamous cell carcinoma (BR/UR ESCC). This research plans to enroll at least 39 evaluable cases or a total of 39 cases in two seperated stages, focusing on patients with thoracic BR/UR ESCC. Patients will receive a single fraction of ILDR with a mean dose of 1 Gy, concurrently with 3 cycles of albumin-bound paclitaxel (260 mg/m² on day 1), cisplatin (75 mg/m² on day 1), and tislelizumab (200 mg on day 1). The efficacy and safety of the treatment will be evaluated throughout the study.

Participants needed: 39
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Chuangzhen ChenUpdated: Oct 5, 2026Locations: 1
Eligibility criteria

Patients voluntarily enroll in this study, sign an informed consent form, and de... [+17]

Patients with distant metastases other than supraclavicular lymph node metastase... [+14]

Status: Recruiting

Long-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority Trial

With the title of "Long-Term Outcomes of endoscopic-assisted vs conventional breast-conserving surgery in breast cancer patients after neoadjuvant therapy: a randomized, multicenter, open label, non-inferiority trial", this study targets breast cancer patients after neoadjuvant therapy. A total of 804 eligible patients, after screening with inclusion and exclusion criteria, will be randomly assigned to Endoscopic-assisted breast conserving surgery(E-BCS) or conventional breast conserving surgery (C-BCS) group at a 1:1 ratio using stratified block randomization method, stratified by centers and molecular subtype. The co-primary endpoints are 5-year disease-free survival (5y-DFS) and Breast-Q score at 6 months after surgery. The secondary endpoints are cosmetic outcomes including surgeons' satisfaction with breast and patients' satisfaction with scar, survival outcomes including 5-year overall survival (5y-OS) and 5-year local-recurrence rate (5y-LRR), surgical outcomes including operative time, intraoperative blood loss, incision length and postoperative complications rate. This study aims to confirm the long-term safety and aesthetic outcome of endoscopic-assisted surgery in breast cancer patients after neoadjuvant treatment by comparing it with conventional open breast conserving surgery, and provide clinical evidence for the popularized application of endoscopic breast surgery.

Participants needed: 804
Trial details
Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUpdated: Sep 30, 2026Locations: 2
Eligibility criteria

Age ranging from 18 to 75 years [+7]

Diffusely disseminated malignant calcification foci [+4]

Status: Not yet recruiting

Augmented Reality Dentistry

This study aims to evaluate the accuracy of augmented reality (AR)-assisted dental procedures. Patient-specific anatomical data will be acquired using cone-beam computed tomography (CBCT) and intraoral scanning and integrated to create a three-dimensional virtual model for treatment planning. Different dental procedures, including tooth extractions, dental implant placement, and orthodontic procedures, will be virtually planned before treatment. During the clinical procedure, the planned anatomical and procedural information will be visualized through an AR system, providing real-time guidance to the operator. The accuracy of AR-assisted treatment will be assessed by comparing the preoperative virtual plan with the postoperative clinical outcome, evaluating deviations between planned and achieved results.

Participants needed: 10
Trial details
Biological sex: AllType: InterventionalSponsor: University of Bari Aldo MoroUpdated: Sep 25, 2026Locations: 1
Eligibility criteria

Good health according to the System of the American Society of Anesthesiology [+2]

Pregnancy [+1]

Status: Recruiting

Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)

standard paradigm for management of patients who present with concern for recurrence of brain metastases following initial stereotactic radiosurgery (SRS).

Participants needed: 155
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Sep 18, 2026Locations: 1
Eligibility criteria

Ability to understand and the willingness to sign a written informed consent doc... [+10]

Patients with brain metastases from hematologic malignancies due to significant... [+5]

Status: Recruiting

Radiofrequency Ablation Versus Hemithyroidectomy for Small Thyroid Cancers

This is a multicenter randomized controlled trial including patients with small (\<2 cm) suspected or confirmed thyroid cancers. Patients are included after informed consent and randomized to one of two treatments. One treatment is a standard henithyroidectomy and the second treatment is radiofrequency ablation (RFA) of the specific tumor. The investigators will evaluate initial outcome of the allocated treatment, thyroid hormonal function, oncologic safety, quality of life, and treatment costs in a follow-up period of five years after treatment. The overall aim of the study is to improve patient's health by reducing the number of operations on small thyroid cancers. In patients with these small tumors, the long-term adverse outcome may be higher than possible benefits from the operation. For participants undergoing surgical treatment with HT, the investigators will measure final histology and both beneficial and adverse outcome from the operation. For participants undergoing RFA, the investigators expect to reduce the need for thyroid hormonal substitutions, reduce the surgical adverse outcomes, reduce treatment costs and increase QoL without a reduction in oncologic safety and outcome.

Participants needed: 88
Trial details
Age: 30+Biological sex: AllType: InterventionalSponsor: University of AarhusUpdated: Sep 15, 2026Locations: 1
Eligibility criteria

Single tumor in the thyroid gland with a FNAB suspecious of cancer or diagnostic... [+1]

suspicion of disseminated disease because of PET-positive lymph nodes ; suspect... [+3]

Status: Recruiting

COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study

Patients with oligoprogression of metastatic breast cancer during palliative treatment that is amenable to local therapy will be included. The local ablative therapy (LAT) may consist of stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy, surgery or percutaneous ablation.

Participants needed: 56
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: The Netherlands Cancer InstituteUpdated: Sep 11, 2026Locations: 7
Eligibility criteria

Histologically confirmed invasive breast cancer [+13]

Having received more than two lines of systemic therapy for MBC If a treatment r... [+4]

Status: Recruiting

Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma

Purpose of the Study: This clinical study investigates whether a shorter or longer duration of systemic therapy before local treatment (surgery or radiation) results in better disease control in patients with esophageal or gastric cancer with a limited number of metastases, also known as oligometastases. Background: In about 25% of patients with advanced esophageal or gastric cancer, the disease spreads to only a few sites (oligometastatic disease). Prior studies suggest that local treatment after systemic therapy may extend survival in this subgroup. However, it is unclear how long systemic therapy should last before initiating local treatment. The OMEC-5 study aims to clarify this. Study Design: Initiated by Amsterdam UMC and UMCU and conducted in multiple hospitals across Europe. Total of 414 patients to be enrolled. Duration: \~53 months (35 months enrollment + 18 months follow-up). Approved by the medical ethics committee at Amsterdam UMC. Procedure: Eligibility screening: Includes physical exam, blood tests (incl. circulating tumor cells), medical history review, and confirmation of oligometastases by an expert panel. Initial treatment: All participants receive 4 months of standard systemic therapy (chemotherapy + immunotherapy and/or targeted therapy depending on tumor markers like HER2 or Claudin 18.2). Response assessment (Review 1): Imaging and/or laparoscopic examination. If oligometastases persist and tumors have not progressed, participants are randomized into two groups: Group A (longer systemic therapy): 4 more months of systemic therapy, then local treatment if disease is stable, followed by 4 months of immunotherapy ± targeted therapy. Group B (shorter systemic therapy): Immediate local treatment followed by 4 months of systemic therapy, then reassessment and potentially 4 months of immunotherapy ± targeted therapy. Follow-up: Regular scans and quality-of-life questionnaires (5 times), and periodic blood sampling (4 times). Treatments Involved: Chemotherapy: CapOx or FOLFOX Immunotherapy: nivolumab or pembrolizumab Targeted therapy: trastuzumab (HER2-positive) or zolbetuximab (Claudin 18.2-positive) Potential Benefits and Risks: Patients may benefit from better disease control and a personalized treatment strategy. Known side effects relate to the standard treatments used (chemo, immuno, targeted therapies), and no extra medical risk is expected beyond routine care. Possible inconveniences include blood draws, scans, minor surgery (laparoscopy), and time investment. Data and Sample Handling: Personal data and tumor/blood samples for exploratory research (if patients consent) are coded and securely stored. Data may be used for future cancer research if the patient consents. Participants can withdraw at any time. Confidentiality and Privacy: Patient data are kept confidential, and participants have rights to access or delete their data. Privacy measures comply with GDPR and Dutch law. Compensation and Insurance: Participation is voluntary, with no financial compensation. Standard treatment costs are covered by healthcare insurance. No extra insurance is required, as the treatment aligns with standard care practices.

Participants needed: 290
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Updated: Sep 10, 2026Locations: 5
Eligibility criteria

Age ≥18 years [+17]

Squamous cell carcinoma [+16]

Status: Recruiting

Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Over 60% of head and neck squamous cell carcinoma (HNSCC) patients are diagnosed at a locally advanced stage. While standard treatments involve surgery and chemoradiotherapy, prognosis remains poor, with 50-60% experiencing local recurrence within two years. Neoadjuvant therapy can potentially reduce tumor burden, preserve organs, and lower distant metastasis risk. Despite the KEYNOTE-689 trial showing that adjuvant two-cycle pembrolizumab increased major pathological response to 9.8% in stage III-IVB HNSCC, this result remains insufficient. More effective immunotherapy-based combinations are urgently needed to improve long-term survival after neoadjuvant treatment. Preclinical and clinical evidence indicates that low-dose radiotherapy can activate the tumor immune microenvironment and synergize with immunotherapy. Based on this rationale, the present clinical trial will evaluate a neoadjuvant regimen combining LDRT with two cycles of an anti-PD-1 inhibitor in patients with surgically resectable, locally advanced HNSCC.

Participants needed: 22
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Rui YouUpdated: Sep 1, 2026Locations: 1
Eligibility criteria

Voluntarily sign and date the informed consent form. [+9]

Pregnant or lactating women. [+11]

Status: Not yet recruiting

Comparison of an Initial Active Follow-up and Therapeutic Care on Functional Outcome and Quality of Life in Patients With Head and Neck Paragangliomas

Head and neck paragangliomas (HNPGs) are predominantly non-secreting, benign and slow-growing tumors. Although most patients remain asymptomatic, up to 30% develop symptoms related to local tumor growth and fewer than 5-10% develop metastatic disease. Surgery has long been considered the standard treatment, while radiotherapy and active surveillance represent alternative management strategies. Treatment-related morbidity and impaired quality of life have been reported in patients with HNPGs; however, the impact of immediate intervention compared with an initial active surveillance strategy has not been prospectively evaluated. This multicenter randomized controlled trial aims to compare active surveillance with immediate intervention in patients with newly diagnosed carotid or vagal paragangliomas. The study hypothesis is that an initial active surveillance strategy increases the time before functional outcome deterioration, particularly ENT-related symptoms, while not resulting in a higher complication rate when treatment is subsequently performed. Eligible patients will undergo baseline assessment including a specialized ENT examination to evaluate cranial nerve function and cervical MRI (or contrast-enhanced CT when MRI is contraindicated) to confirm tumor location, size, and the absence of lymphadenopathy or atypical imaging features. After providing written informed consent, participants will be centrally randomized in a 1:1 ratio, stratified by study center and tumor location, to either active surveillance or immediate intervention. Patients assigned to active surveillance will undergo regular clinical and radiological follow-up, with treatment initiated only if disease progression or symptom development warrants intervention. Patients assigned to immediate intervention will receive surgery or radiotherapy according to multidisciplinary team recommendations and local practice, within six months after randomization. Patients who decline participation in the randomized trial, as well as those who are not eligible for randomization, may be offered participation in a parallel observational study collecting clinical, imaging, treatment and outcome data according to routine practice. Patient quality of life will also be assessed throughout the study (experimental and observational) using validated questionnaires.

Participants needed: 122
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Hospices Civils de LyonUpdated: Aug 25, 2026Locations: 8
Eligibility criteria

Patients ≥ 18 years-old, [+5]

Patient with initial nerve palsy due to the evaluated HNPG, [+15]

Status: Recruiting

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant stereotactic body radiotherapy (SBRT) followed by nab-paclitaxel combined with toripalimab in patients with previously untreated HR+/HER2-negative breast cancer. Eligible patients include those with stage IIB-IIIC disease (cT3N0, cT2-4N1-3 or cT1N2-3) or stage IIA disease (cT2N0 or cT1N1) with at least two of the following high-risk factors: histologic grade 3, Ki-67 ≥50% or premenopausal with age \<50 years. A total of 27 enrolled patients will be assigned to receive the combination therapy. The primary question it aims to answer is whether this combination of radiotherapy, de-escalated chemotherapy, and immunotherapy can improve the total pathologic complete response (tpCR) rate (defined as ypT0/Tis ypN0).

Participants needed: 27
Trial details
Phase: Phase 2Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Xijing HospitalUpdated: Aug 14, 2026Locations: 2
Eligibility criteria

Female patients aged ≥18 and ≤75 years at the time of signing informed consent. [+15]

Inflammatory Breast Cancer. [+20]